IP Library Granted Patent US 11,654,196
Granted Patent B2
US 11,654,196 · App. 16/920,316 · Granted May 23, 2023

Dosing regimens for echinocandin class compounds

Inventors: Balasingam Radhakrishnan (Chapel Hill, NC); Kenneth Duke James, Jr. (Mebane, NC); Anuradha Vaidya (Raleigh, NC); Karen Polowy (Raleigh, NC)
Assignee: Cidara Therapeutics, Inc.
A61K47/186A61K9/006A61K9/0019A61K9/0053A61K9/0095A61K9/06A61K9/107A61K9/19A61K9/2018A61K38/08A61K38/12A61K47/10A61K47/12A61K47/14A61K47/183A61K47/26A61K47/36A61M5/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,654,196
App. No.
16/920,316
Granted
May 23, 2023
Kind
B2
Abstract

The invention features pharmaceutical compositions, methods, and kits featuring dosing gimens and oral dosage formulations for administration of echinocandin class compounds.

Claims (6)

1. A method of treating or preventing a fungal infection in a subject, the method comprising administering to the subject by intravenous infusion an aqueous solution comprising from 0.50 mg/mL to 3 mg/mL of compound 22 having the structure:

or a pharmaceutically acceptable salt thereof.

2. A method of treating or preventing a fungal infection in a subject, the method comprising administering to the subject by intravenous bolus an aqueous solution comprising from 25 mg/mL to 500 mg/mL of compound 22 having the structure:

or a pharmaceutically acceptable salt thereof.

3. A device for injecting into a subject an aqueous solution comprising compound 22 having the structure:

or a pharmaceutically acceptable salt thereof, wherein the device comprises a container holding from 0.05 mL to 10 mL of said aqueous solution and a needle.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2024
From: CIDARA THERAPEUTICS, INC.
To: NAPP PHARMACEUTICAL GROUP LIMITED
Reel/Frame 069208/0471 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2023
From: RADHAKRISHNAN, BALASINGAM; JAMES, KENNETH DUKE, JR.; VAIDYA, ANURADHA; POLOWY, KAREN
To: SEACHAID PHARMACEUTICALS, LLC
Reel/Frame 064237/0345 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2023
From: RADHAKRISHNAN, BALASINGAM; JAMES, KENNETH DUKE, JR.; VAIDYA, ANURADHA; POLOWY, KAREN
To: SEACHAID PHARMACEUTICALS, INC.
Reel/Frame 062541/0365 →
CHANGE OF NAME Recorded Oct 22, 2020
From: K2 THERAPEUTICS, INC.
To: CIDARA THERAPEUTICS, INC.
Reel/Frame 054179/0621 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2020
From: RADHAKRISHNAN, BALASINGAM; JAMES, KENNETH DUKE, JR.; VAIDYA, ANURADHA; POLOWY, KAREN
To: SEACHAID PHARMACEUTICALS, LLC
Reel/Frame 054139/0021 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2020
From: SEACHAID PHARMACEUTICALS, LLC
To: K2 THERAPEUTICS, INC.
Reel/Frame 054139/0192 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2020
From: SEACHAID PHARMACEUTICALS, LLC
To: CIDARA THERAPEUTICS, INC.
Reel/Frame 054139/0765 →
Continuity (6)
Continuation 16017427 · Jun 25, 2018
Continuation 15371333 · Dec 7, 2016
Continuation 14386266
Provisional Application 61707142 · Sep 28, 2012
Provisional Application 61612676 · Mar 19, 2012
Related Publication 20210128670A1 · May 6, 2021